BioNTech SE - ADR

NASDAQ:BNTX   9:46:52 AM EDT
108.05
+3.09 (+2.94%)
Other Pre-Announcement

BioNTech Q3 Net Loss Widens To EUR 351.7 Mln

Published: 11/10/2020 12:35 GMT
BioNTech SE (BNTX) - Biontech Announces Third Quarter 2020 Financial Results and Corporate Progress.
Bnt162b2 Vaccine Candidate Was Found to Be More Than 90% Effective in Preventing Covid-19 in Participants Without Evidence of Prior Sars-cov-2 Infection in First Interim Efficacy Analysis From Phase 3 Trial.
Closed Equity and Debt Financings and Secured Grant Commitments of Approximately $1.2 Billion(1) (eur 1.0 Billion) in Combined Gross Proceeds, Resulting in Net Cash Receipts of $0.8 Billion(1) (eur 0.6 Billion) in Q3.
Analysis Evaluated 94 Confirmed Cases of Covid-19 in Trial Participants.
Study Enrolled 43,538 Participants With 42% Having Diverse Backgrounds and No Serious Safety Concerns Have Been Observed.
For Period of Nine Months Ended September 30, 2020, Total Revenue Was EUR 136.9 Million, Compared to EUR 80.6 Million for Comparative Prior Year Period.
Submission for Emergency Use Authorization (eua) to U.S. Food and Drug Administration (fda) Planned for Soon After Required Safety Milestone is Achieved, Which is Currently Expected to Occur in Third Week of November.
For Period of Nine Months Ended September 30, 2020, Total Net Loss Was EUR 351.7 Million, Compared to EUR 120.9 Million for Comparative Prior Year Period.
For Period of Nine Months Ended September 30, 2020, Total Revenue Was EUR 136.9 Million, Compared to EUR 80.6 Million for Comparative Prior Year Period.